Last reviewed · How we verify
A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) (CTTNKTL-Ⅲ/Ⅳ)
The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer (NK)/T Cell Lymphoma.
Details
| Lead sponsor | Mingzhi Zhang |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 80 |
| Start date | 2011-01 |
| Completion | 2019-05 |
Conditions
- Nasal and Nasal-type NK/T-cell Lymphoma
Interventions
- DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)
- Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
Primary outcomes
- Progression-free survival — up to end of follow-up-phase (approximately 24 months)
Countries
China